Abstract
Purpose: To summarise the practical aspects of the development of techniques of interstitial permanent prostate brachytherapy (PPB) implantation. Prostate brachytherapy dates back to Pasteau's publication in 1913 describing the insertion of a radium capsule into the prostatic urethra to treat carcinoma of the prostate. Various implantation methods were employed but with unsatisfactory results until the development of the transrectal ultrasound in the 1980s. The subsequent two-stage Seattle technique allowed for a planned homogenous distribution of radioactive sources throughout the gland resulting in biochemical control comparable to surgical and external beam radiotherapy series. With the advent of advanced computer software and improved imaging, the technique has developed accordingly to a single stage procedure with on-table dosimetric assessment. The principles of targeting dose to the prostate while avoiding surrounding organs at risk remain as relevant today as nearly a century ago. There is an array of techniques to consider for the novice PPB provider. Whether the evolution of PPB techniques will translate into improved biochemical control is yet to be seen.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Porter AT, Blasko JC, Grimm PD, Reddy SM, Ragde H . Brachytherapy for prostate cancer. CA Cancer J Clin 1995; 45: 165–178.
Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58: 25–33.
Sharkey J, Cantor A, Solc Z, Huff W, Chovnick SD, Behar RJ et al. Brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer. Curr Urol Rep 2002; 3: 250–257.
Potters L, Klein EA, Kattan MW, Reddy CA, Ciezki JP, Reuther AM et al. Monotherapy for stage T1–T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 2004; 71: 29–33.
Young HH . The early diagnosis and radical cure of carcinoma of the prostate. Bull Johns Hopkins Univ 1905; 16: 315–321.
Aronowitz JN . Dawn of prostate brachytherapy: 1915–1930. Int J Radiat Oncol Biol Phys 2002; 54: 712–718.
Pasteau O, Degrais P . De I’emploi du radium dans le traitement des cancers de la prostate. J D’urologie Medicale et Chirurgicale 1913; 4: 341–366.
Barringer BS . Radium in the treatment of carcinoma of the bladder and prostate. JAMA 1917; 68: 1227–1230.
Young HH . Treatment of carcinoma of the prostate. In: Young HH, Davis DM (eds). Young's Practice of Urology: Based on a Study of 12 500 Cases. WB Saunders: Philadelphia, 1926, pp 644–671.
Paterson RPH . A dosage system for gamma-ray therapy, Parts I and II. Br J Radiol 1934; 7: 592–632.
Barringer BS . Prostatic carcinoma. J Urol 1942; 47: 306–310.
Deming CL . Radium therapy for prostate cancer: results of the first 100 patients. J Urol 1922; 34: 99–118.
Flocks RH, Kerr HD, Elkins HB, Culp B . Treatment of carcinoma of the prostate by interstitial radiation with radioactive gold (Au198): a preliminary report. J Urol 1952; 68: 510–522.
Whitmore Jr WF, Hilaris B, Grabstald H . Retropubic implantation of iodine 125 in the treatment of prostate cancer. J Urol 1972; 108: 918–920.
Anderson LL . Spacing nomograph for interstitial implants of I-125 seeds. Med Phys 1976; 3: 48–51.
Carlton Jr CE, Dawoud F, Hudgins P, Scott Jr R . Irradiation treatment of carcinoma of the prostate: a preliminary report based on 8 years of experience. J Urol 1972; 108: 924–927.
Zelefsky MJ, Whitmore Jr WF . Long-term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer. J Urol 1997; 158: 23–29.
Blasko JC, Grimm PD, Ragde H . Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Radiat Oncol 1993; 3: 240–249.
Holm HH, Juul N, Pedersen JF, Hansen H, Stroyer I . Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983; 130: 283–286.
Holm HH . The history of interstitial brachytherapy of prostatic cancer. Semin Surg Oncol 1997; 13: 431–437.
Holm HH, Torp-Pedersen S, Myschetzky P . Transperineal seed-implantation guided by biplanar transrectal ultrasound. Urology 1990; 36: 249–252.
Blasko JC, Ragde H, Luse RW, Sylvester JE, Cavanagh W, Grimm PD . Should brachytherapy be considered a therapeutic option in localized prostate cancer? Urol Clin North Am 1996; 23: 633–650.
Wallner K . Prostate brachytherapy under local anesthesia; lessons from the first 600 patients. Brachytherapy 2002; 1: 145–148.
Dattoli M, Waller K . A simple method to stabilize the prostate during transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys 1997; 38: 341–342.
Crook JM, Raymond Y, Salhani D, Yang H, Esche B . Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol 1995; 37: 35–42.
Messing EM, Zhang JB, Rubens DJ, Brasacchio RA, Strang JG, Soni A et al. Intraoperative optimized inverse planning for prostate brachytherapy: early experience. Int J Radiat Oncol Biol Phys 1999; 44: 801–808.
Prestidge BR, Prete JJ, Buchholz TA, Friedland JL, Stock RG, Grimm PD et al. A survey of current clinical practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys 1998; 40: 461–465.
Beaulieu L, Aubin S, Taschereau R, Pouliot J, Vigneault E . Dosimetric impact of the variation of the prostate volume and shape between pretreatment planning and treatment procedure. Int J Radiat Oncol Biol Phys 2002; 53: 215–221.
Grimm PD, Blasko JC, Sylvester JE, Heaney C, Gasparich J, Quackenbush J et al. Technical improvement in permanent seed implantation: a two-stage brachytherapy system. Description and comparison with current technique. Brachytherapy 2004; 3: 34–40.
Kaplan ID, Holupka EJ, Meskell P, Soon SJ, Saltzman B, Church P et al. Intraoperative treatment planning for radioactive seed implant therapy for prostate cancer. Urology 2000; 56: 492–495.
Stock RG, Stone NN, Wesson MF, DeWyngaert JK . A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 1995; 32: 219–225.
Stone NN, Ramin SA, Wesson MF, Stock R, Unger P, Klein G . Laparoscopic pelvic lymph node dissection combined with real-time interactive transrectal ultrasound guided transperineal radioactive seed implantation of the prostate. J Urol 1995; 153: 1555–1560.
Stone NN, Roy J, Hong S, Lo YC, Stock RG . Prostate gland motion and deformation caused by needle placement during brachytherapy. Brachytherapy 2002; 1: 154–160.
Stone NN, Hong S, Lo YC, Howard V, Stock RG . Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy. Brachytherapy 2003; 2: 17–25.
Stock RG, Stone NN, Lo YC, Malhado N, Kao J, DeWyngaert JK . Postimplant dosimetry for (125)I prostate implants: definitions and factors affecting outcome. Int J Radiat Oncol Biol Phys 2000; 48: 899–906.
Stock RG, Stone NN, Tabert A, Iannuzzi C, DeWyngaert JK et al. A dose–response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 1998; 41: 101–108.
Matzkin H, Kaver I, Bramante-Schreiber L, Agai R, Merimsky O, Inbar M . Comparison between two iodine-125 brachytherapy implant techniques: pre-planning and intra-operative by various dosimetry quality indicators. Radiother Oncol 2003; 68: 289–294.
Gewanter RM, Wuu C, Laguna JL, Katz AE, Ennis RD . Intraoperative preplanning for transperineal ultrasound-guided permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000; 48: 377–380.
Wilkinson DA, Lee EJ, Ciezki JP, Mohan DS, Zippe C, Angermeier K et al. Dosimetric comparison of pre-planned and or-planned prostate seed brachytherapy. Int J Radiat Oncol Biol Phys 2000; 48: 1241–1244.
Beyer DC, Shapiro RH, Puente F . Real-time optimized intraoperative dosimetry for prostate brachytherapy: a pilot study. Int J Radiat Oncol Biol Phys 2000; 48: 1583–1589.
Yamada Y, Potters L, Zaider M, Cohen G, Venkatraman E, Zelefsky MJ . Impact of intraoperative edema during transperineal permanent prostate brachytherapy on computer-optimized and preimplant planning techniques. Am J Clin Oncol 2003; 26: e130–e135.
Zelefsky MJ, Yamada Y, Cohen G, Venkatraman ES, Fung AY, Furhang E et al. Postimplantation dosimetric analysis of permanent transperineal prostate implantation: improved dose distributions with an intraoperative computer-optimized conformal planning technique. Int J Radiat Oncol Biol Phys 2000; 48: 601–608.
Zelefsky MJ, Yamada Y, Marion C, Sim S, Cohen G, Ben Porat L et al. Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003; 55: 956–963.
Cormack RA, Kooy H, Tempany CM, D’Amico AV . A clinical method for real-time dosimetric guidance of transperineal 125I prostate implants using interventional magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2000; 46: 207–214.
Nag S, Ciezki JP, Cormack R, Doggett S, DeWyngaert K, Edmundson GK et al. Intraoperative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 2001; 51: 1422–1430.
Stock RG, Stone NN . Importance of post-implant dosimetry in permanent prostate brachytherapy. Eur Urol 2002; 41: 434–439.
Potters L, Calguaru E, Thornton KB, Jackson T, Huang D . Toward a dynamic real-time intraoperative permanent prostate brachytherapy methodology. Brachytherapy 2003; 2: 172–180.
Potters L . Permanent prostate brachytherapy in men with clinically localised prostate cancer. Clin Oncol (R Coll Radiol) 2003; 15: 301–315.
Chauveinc L, Flam T, Solignac S, Thiounn N, Firmin F, Debre B et al. Prostate cancer brachytherapy: is real-time ultrasound-based dosimetry predictive of subsequent CT-based dose distribution calculation? A study of 450 patients by the Institut Curie/Hospital Cochin (Paris) Group. Int J Radiat Oncol Biol Phys 2004; 59: 691–695.
Potters L, Cao Y, Calugaru E, Torre T, Fearn P, Wang XH . A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2001; 50: 605–614.
Stock RG, Stone NN, Dahlal M, Lo YC . What is the optimal dose for 125I prostate implants? A dose–response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms. Brachytherapy 2002; 1: 83–89.
Ragde H, Korb LJ, Elgamal AA, Grado GL, Nadir BS . Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer 2000; 89: 135–141.
Hilaris BS, Whitmore Jr WF, Batata MA, Grabstald H et al. Radiation therapy and pelvic node dissection in the management of cancer of the prostate. Am J Roentgenol Radium Ther Nucl Med 1974; 121: 832–838.
Glasser O, Quimby EH, Taylor LS, Weatherwax JL, Morgan RH . Physical Foundations of Radiology. Harper and Row: New York, 1961.
Meredith WJ . Radium Dosage – the Manchester System. E. and S. Livingstone: Edinburgh, 1967.
Roy JN, Wallner KE, Harrington PJ, Ling CC, Anderson LL et al. A CT-based evaluation method for permanent implants: application to prostate. Int J Radiat Oncol Biol Phys 1993; 26: 163–169.
Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS . Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys 1995; 22: 209–234.
Luse RW, Blasko J, Grimm P . A method for implementing the American Association of Physicists in Medicine Task Group-43 dosimetry recommendations for 125I transperineal prostate seed implants on commercial treatment planning systems. Int J Radiat Oncol Biol Phys 1997; 37: 737–741.
Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W . 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 2001; 51 (1): 31–40.
Stone NN, Stock RG, Unger P . Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer. J Urol 2005; 173 (3): 803–807.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Prostate Cancer and Prostatic Diseases website (http://www.nature.com/pcan)
Rights and permissions
About this article
Cite this article
Acher, P., Morris, S., Popert, R. et al. Permanent prostate brachytherapy: a century of technical evolution. Prostate Cancer Prostatic Dis 9, 215–220 (2006). https://doi.org/10.1038/sj.pcan.4500873
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4500873
Keywords
This article is cited by
-
Zur frühen Entwicklung der Brachytherapie der Prostata
Der Urologe (2013)
-
Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer
Journal of Cancer Research and Clinical Oncology (2011)